



NOTICE TO THE MARKET

JBS ENTERS THE CULTIVATED PROTEIN MARKET WITH US\$100 MILLION INVESTMENT

The investments include the acquisition of Bio Tech Foods, the construction of a plant in Europe and the implementation of a Research and Development Center in Brazil

JBS S.A. ("**JBS**" – B3: JBSS3; OTCQX: JBSAY) hereby communicates to its shareholders and to the market, in accordance with the terms of the Brazilian Securities Commission (CVM) Resolution no. 44 dated August 23, 2021, that its controlled entity JBS Global Luxembourg S.à r.l. has entered into an agreement to acquire the control of the Spanish company BioTech Foods, S.L. ("**Biotech Foods**"). The acquisition marks the company's entry into the cultivated protein market, which consists of the production of food from animal cells, and includes a US\$41 million investment in the construction of a new plant in Spain to scale up production. Besides the acquisition, JBS also announces the implementation of the first Center for Research and Development (R&D) in biotechnology and cultivated protein in Brazil.

BioTech Foods is one of the leaders in the development of biotechnology for the production of cultivated protein. Founded in 2017, the company operates a pilot plant in the Spanish city of San Sebastián, and is expected to reach commercial production by mid-2024 when the cultivated protein will reach consumers in the form of various prepared foods, such as hamburgers, sausages, meatballs, among others, with the same quality, safety, flavor and texture of traditional protein. The technology has potential not only for the production of beef protein, but also for chicken, pork and fish. Under the terms of the transaction, JBS shall become the majority shareholder of BioTech Foods.

The closing of this transaction is subject to the confirmation from Spain's foreign direct investment authorities, among other usual conditions for this type of transaction.

Through the investment in the Cultivated Protein Research Center in Brazil, expected to inaugurate in 2022, JBS intends to develop new techniques that accelerate scale gains and reduce the production costs of the cultivated protein, anticipating its commercialization in the market.

In total, JBS will invest US\$100 million towards the two initiatives, which are aligned to JBS's strategy of expanding its platform of new forms of protein production, as a reflection of new consumption trends and population growth in the coming decades.

São Paulo, November 17, 2021

Guilherme Perboyre Cavalcanti
Investor Relations Officer